Cytokinetics (NASDAQ:CYTK) Posts Earnings Results

Cytokinetics (NASDAQ:CYTK) released its earnings results on Wednesday. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.44) by $0.07, Zacks reports. The firm had revenue of $47.56 million during the quarter, compared to analyst estimates of $41.88 million. Cytokinetics’s revenue was up 2356.5% on a year-over-year basis. During the same period in the previous year, the company earned ($2.55) earnings per share.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO generated $44.5 million in Q3 net product revenue, up 76% sequentially. Prescribers and dispensed patients grew, while new-to-brand share approached 45%; the company is targeting more than 50% by year-end.
• Cytokinetics plans to submit an aficamten supplemental NDA for symptomatic non-obstructive HCM this quarter, following positive Phase 3 ACACIA-HCM results. The company is also preparing for a potential 2027 launch, though approval and the eventual label remain uncertain.
• MYQORZO’s international rollout is progressing, with Germany showing early traction and a U.K. launch expected this quarter. The company expects launches in additional countries in 2027, while noting broader European revenue may take until 2028–2029 to build meaningfully.
• The company ended Q3 with approximately $1.6 billion in cash and investments and reaffirmed 2026 combined R&D and SG&A expense guidance of $860 million–$890 million. Quarterly SG&A increased to $113.1 million as commercial launch costs rose, while the company reported a $190.1 million net loss.

Cytokinetics Stock Performance

Shares of Cytokinetics stock traded up $1.29 on Wednesday, hitting $63.60. The company’s stock had a trading volume of 2,916,652 shares, compared to its average volume of 1,525,180. The company has a market capitalization of $7.91 billion, a price-to-earnings ratio of -8.81 and a beta of 0.45. Cytokinetics has a 1 year low of $58.05 and a 1 year high of $88.31. The firm has a fifty day moving average price of $66.63 and a 200-day moving average price of $70.05.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, better than analysts’ expected loss of $1.44, and revenue of $47.56 million versus estimates of $41.88 million. Revenue rose 2,356.5% year over year, and the per-share loss narrowed from $2.55 in the year-ago quarter. Earnings report
• Neutral Sentiment: CEO Robert Blum and EVP Fady Malik sold shares under pre-arranged Rule 10b5-1 trading plans. The sales totaled 7,500 and 3,500 shares, respectively; both executives retained substantial holdings, which may reduce the significance of the transactions. Insider sale report

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC upped their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Citigroup restated a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a report on Friday, September 11th. Finally, Truist Financial increased their price target on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.44.

Insiders Place Their Bets

In other news, EVP Andrew Callos sold 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $70.24, for a total value of $702,400.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares in the company, valued at $4,112,903.20. This represents a 14.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Blum sold 97,926 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $69.33, for a total value of $6,789,209.58. Following the transaction, the chief executive officer directly owned 385,320 shares in the company, valued at $26,714,235.60. This trade represents a 20.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 180,926 shares of company stock worth $12,510,340. Corporate insiders own 2.60% of the company’s stock.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.